use of tumor markers in testicular, prostate, colorectal, breast, and ...

More documents

Recommendations

Info

National Academy of Clinical Biochemistry Presents LABORATORY MEDICINE PRACTICE GUIDELINES USE OF TUMOR MARKERS IN TESTICULAR, PROSTATE, COLORECTAL, BREAST, AND OVARIAN CANCERS Catharine M. Sturgeon Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK Michael J. Duffy Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland Ulf-Håkan Stenman Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland Hans Lilja Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Nils Brünner Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark Daniel W. Chan Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD Richard Babaian Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX EDITED BY Catharine M. Sturgeon Eleftherios P. Diamandis Robert C. Bast, Jr Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX Barry Dowell Abbott Laboratories, Abbott Park, IL Francisco J. Esteva Departments of Breast Medical Oncology, Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX Caj Haglund Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland Nadia Harbeck Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Munich, Germany Daniel F. Hayes Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Mads Holten-Andersen Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark George G. Klee Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Rolf Lamerz Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany Leendert H. Looijenga Laboratory of Experimental Patho-Oncology, Erasmus MC-University Medical Center Rotterdam, and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands Rafael Molina Laboratory of Biochemistry, Hospital Clinico Provincial, Barcelona, Spain Hans Jørgen Nielsen Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen, Denmark Harry Rittenhouse Gen-Probe Inc, San Diego, CA Axel Semjonow Prostate Center, Department of Urology, University Clinic Muenster, Muenster, Germany Ie-Ming Shih Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD Paul Sibley Siemens Medical Solutions Diagnostics, Glyn Rhonwy, Llanberis, Gwynedd, UK György Sölétormos Department of Clinical Biochemistry, Hillerød Hospital, Hillerød, Denmark Carsten Stephan Department of Urology, Charité Hospital, Universitätsmedizin Berlin, Berlin, Germany Lori Sokoll Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD Barry R. Hoffman Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada Eleftherios P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
Page 1: The National Academy of Clinical Bi
Page 5: Table of Contents 1. Introduction 1
Page 9 and 10: Chapter 2 Tumor Markers in Testicul
Page 11 and 12: Table 2. Recommendations for Use of
Page 13 and 14: Tumor Markers in Testicular Cancers
Page 19: Tumor Markers in Testicular Cancers
Page 22 and 23: 16 Use of Tumor Markers in Testicul
Page 24 and 25: Table 8. Biomarkers Currently Being
Page 33 and 34: Chapter 4 Tumor Markers in Colorect
Page 35 and 36: Fecal Markers FOBT Screening asympt
Page 37 and 38: Table 10. Recommendations for Use o
Page 39 and 40: Tumor Markers in Colorectal Maligna
Page 41: Tumor Markers in Colorectal Maligna
Page 44 and 45: Table 11. Useful and Potentially Us
Page 46 and 47: Table 11. Useful and Potentially Us
Page 48 and 49: Table 12. Recommendations for Use o
Page 52 and 53:
46 Use of Tumor Markers in Testicul
Page 54 and 55:
Page 57 and 58:
Chapter 6 Tumor Markers in Ovarian
Page 59 and 60:
Table 16. Recommendations for Use o
Page 61 and 62:
Tumor Markers in Ovarian Cancer 55
Page 63 and 64:
Page 65:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Acknowledgment We would like to tha
Page 88 and 89:
show all

use of tumor markers in testicular, prostate, colorectal, breast, and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?